GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Panacea Biotec Ltd

Panacea Biotec: AY 2016-17 tax demand of ₹10.23 Crore rectified to Nil

REGULATORY ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 07 Apr 2026, 11:54 AM IST  ·  BSE ID: c61a7a57-45da-433d-bdc4-c35fd21c1a2f
View Original BSE Filing (PDF)
💡
In Simple Terms
The tax department initially claimed the company owed ₹10.23 Crore for year 2016-17, but after the company pointed out calculation errors, the demand has been erased to zero.
🤖 AI Summary
  • DCIT issued rectified Assessment Order dated 06.04.2026 reducing AY 2016-17 tax demand to Nil
  • Original demand was approximately ₹10.23 Crore issued 01.03.2026 for disallowed expenditure
  • Company's rectification application corrected double addition of disallowances and brought-forward loss omission
  • Tax liability for Assessment Year 2016-17 determined as Nil — demand completely reversed
  • Company confirms no adverse impact on financial, operational, or other activities from order
🔢 Key Numbers — exact figures from BSE filing, not rounded
Original tax demand (AY 2016-17)
~₹10.23 Crore
Rectified tax liability (AY 2016-17)
Nil
Assessment Year
2016-17
Date of rectified order
06.04.2026
🏢 How This Affects the Company
💰
Financial Impact
Removal of ₹10.23 Crore tax demand for AY 2016-17 eliminates a contingent liability previously flagged. This reduces the company's exposure on this assessment year and improves financial clarity.
⚠️
Risk Impact
Resolution of this AY 2016-17 assessment removes a specific tax dispute. However, the company continues to face other pending tax and GST demands across multiple assessment years as disclosed in March 2026 filings.
👥 What This Means For Shareholders
✅
Action Required
No action required. This is an informational disclosure of a resolved tax matter.
👤
Who Is Affected
All shareholders benefit from elimination of this ₹10.23 Crore contingent liability, which reduces the company's total tax exposure and improves balance sheet clarity.
🔍
Management Signal
Management exercised proper due diligence by filing a rectification application and demonstrating ability to identify and correct tax authority errors within 36 days of the original demand.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Monitor outcome of High Court writ petition on ₹22.88 Crore GST demand (interim stay active)
Track progress of appeal with higher tax authority on ₹9.38 Crore penalty demand from March 2026
Watch for any further rectification filings or status updates on pending AY 2015-16 and GST matters
MEDIUM RISK While AY 2016-17 is resolved, company faces ₹32.27 Crore GST exposure, ₹9.38 Crore penalty upheld, and ₹22.88 Crore GST demand under interim stay. Pattern suggests material compliance exposure.
💡 Investor Takeaway
Panacea Biotec's ₹10.23 Crore AY 2016-17 tax demand has been eliminated following rectification of calculation errors by the tax authority. The company's tax liability for that year is now Nil. However, ongoing disputes remain: AY 2015-16 demand (₹45.71 Crore rectified to Nil but with ₹32.27 Crore GST exposure) and ₹9.38 Crore penalty upheld by appeals court.
⚖️ Strengths & Concerns

✅ Positives

  • Rectification successfully eliminated entire ₹10.23 Crore tax demand for AY 2016-17 through proper application process
  • Company demonstrated diligence in identifying and correcting administrative errors in assessment order within 36 days

⚠️ Concerns

  • Company still faces ₹45.71 Crore AY 2015-16 demand (separately rectified to Nil), ₹32.27 Crore GST exposure, and ₹9.38 Crore penalty upheld by appeals court
  • Multiple ongoing tax disputes across consecutive assessment years indicate systemic compliance or documentation issues requiring resolution
📅 Company Track Record
Panacea Biotec has disclosed multiple tax disputes within 5 days: (1) March 06, 2026 — AY 2016-17 demand ₹10.23 Crore rectified to Nil by DCIT (April 06, 2026); (2) March 27, 2026 — ₹9.38 Crore penalty demand upheld by tax appeals court; (3) March 31, 2026 — ₹22.88 Crore GST demand issued with High Court interim stay. Company is also managing ₹45.71 Crore AY 2015-16 exposure with ₹32.27 Crore GST and penalty component remaining.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.